| Document |
Document Title |
|
WO/2007/022030A2 |
The present invention provides methods of carrying out the safe and reliable preparation of lipids comprising quaternary amines. Such lipids are especially suited for introducing therapeutic agents into cells or organisms. In particular,...
|
|
WO/2007/017670A1 |
Compounds of formula (I) have muscarinic M3 receptor modulating activity; Formula(I) wherein A is an oxygen atom or group -N(R12)-;(i) R1 is C1-C6-alkyl or a hydrogen atom; and R2 is a hydrogen atom or a group -R5, -Z-Y-R5 -Z-NR9R10; -Z-...
|
|
WO/2006/133652A1 |
Compounds of the general formula (I), optical isomers, pharmaceutically acceptable salts, preparation process and uses thereof in which R1, R2, R3 and R4 are as defined in specification are disclosed. Such compounds can be optical isomer...
|
|
WO/2006/135694A2 |
Disclosed herein are novel aromatic-containing compounds and methods for using various aromatic-containing compounds for treatment and prevention of diseases and disorders related to the Urotensin II receptor.
|
|
WO/2006/121187A1 |
The present invention provides: an acrylicester compound having a structure represented by General Formula (1) or (2) below ; a latent electrostatic image forming member includes a cured material obtained through a radical polymerization...
|
|
WO/2006/111233A1 |
The invention relates to the use of compounds of formula (I), comprising radicals as defined in the description, which are used as antioxidants, corresponding novel compounds and preparations, in addition to a corresponding production me...
|
|
WO/2006/111234A1 |
The invention relates to the use of compounds which do not display any essential UV-absorption in the UV-A- or UV-B-ranges, but are reactive under conditions of application, in order to produce UV-A- or UV-B- protection during applicatio...
|
|
WO/2006/100225A2 |
Benzoic acid ester compounds of formula (I) wherein R and R1-R5 have the meanings explained in the description, methods for producing them and use thereof in cosmetic, pharmaceutical, personal care and industrial preparations as sunscree...
|
|
WO/2006/056312A1 |
The invention relates to DOTAP chloride that is devoid of enantiomers, in addition to stable crystalline modifications of (2R,S)-, (2S)- and (2R)-DOTAP chloride. The invention also relates to a method for producing said modifications and...
|
|
WO/2006/040332A1 |
The instant invention relates to the use of compounds derived from the esterification reaction of alkoxylated amines and fatty acids, optionally quaternised with an alkylating agent, and of the cationic surfactants and esterquats obtaina...
|
|
WO/2006/040470A1 |
The invention concerns a method for preparing (meth)acrylic esters or anhydrides from acrylic acid of formulae (I), wherein R is H or Me, and R' is alkyl and R'' is alkyl or ethyl substituted by dialkylamino whereof the alkyls can form w...
|
|
WO/2005/118522A1 |
Disclosed are a monomethylphytosphingosine-polyethyleneglycol (MMPS-PEG) derivative formed by combining monomethylphytosphingosine (MMPS), which is a derivative of sphingolipid, with polyethyleneglycol (PEG) or a pharmaceutically accepta...
|
|
WO/2005/105730A2 |
The invention relates to a method of preparing an alcohol from a halogenoaromatic compound and an aldehyde, leading to an $g(a)-hydroxyalkylaromatic compound. According to the invention, the method of preparing an $g(a)-hydroxyalkylaroma...
|
|
WO/2005/095369A1 |
The present invention relates to water soluble esters of [N-(4-amino-2-butynyl)] or 4-(N-substituted amino)-2-butynyl-1-esters and methods for production of said esters and the use of the esters for treatment of cancer.
|
|
WO/2005/077886A1 |
Novel calcilytic compounds and methods of using them are provided.
|
|
WO/2005/075409A1 |
Ibopamine maleate salt (1: 1), method for preparing it and pharmaceutical composition containing it.
|
|
WO/2005/060603A2 |
The invention describes novel pyruvate compounds comprising at least one nitric oxide releasing group and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one pyruvate compound comprising at least one...
|
|
WO/2005/056516A1 |
The present invention relates to novel compounds corresponding to the general formula (I) below: to compositions containing them and to their use in pharmaceutical compositions intended for use in human or veterinary medicine, or alterna...
|
|
WO/2005/053685A1 |
The present invention relates to β-adrenergic blockers nitrooxyderivatives of general formula (I): A-(Y-ONO2)s, wherein s is an integer equal to 1 or 2; A is selected from the following β-adrenergic blockers residues of formula (II), w...
|
|
WO/2005/049549A1 |
A process for the synthesis of lipid cations having general formula (6) in which: R1 represents a lipophilic chain; R2, R3, R4, which are identical or different from one another, represent C1-C10 alkyl, C1-C10 alkenyl, or C1-C10 alkynyl ...
|
|
WO2004110364A9 |
The current invention provides novel thiotungstate derivatives, methods of making novel thiotungstate derivatives, pharmaceutical compositions of novel thiotungstate derivatives, methods of using novel thiotungstate derivatives to treat ...
|
|
WO/2005/030780A1 |
The present invention relates to a method (assay) for determining the activity of an enzyme selected from the group consisting of a sphingosine kinase and a phosphatase involved in the sphingolipid pathway by use of a labeled sphingosine.
|
|
WO/2005/028457A1 |
The present invention discloses a process for the preparation of quetiapine, which comprises the reaction of dibenzo[b,f][1,4]thiazepin-11-ylamine with a compound of the general formula (II) as well as novel intermediates in the process.
|
|
WO/2005/027157A2 |
A salt fusible at ordinary temperature which comprises: a cation ingredient obtained by introducing a cationic group into a volatile organic solvent; and an anion ingredient selected from the group consisting of an inorganic ion, sulfoni...
|
|
WO/2005/023754A1 |
The invention relates to the preparation of (meth)acrylate di-ammonium salts responding to formula (I) wherein R1 represents hydrogen or methyl, each R2 , independently, represents an alkyl comprising from 1 to 4 carbon atoms, each R3, i...
|
|
WO/2005/021051A1 |
The present invention relates to aminoalkyl substituted fumarates and there use as malodor neutralisers.
|
|
WO/2005/019157A1 |
The present invention provides compounds of formula I described herein. The present invention also provides a method of treating a cognitive dysfunction in a mammal. The method includes administering to the mammal an effective amount of ...
|
|
WO/2005/018631A1 |
This invention comprises a novel class of Choline derivatives for the treatment of Alzheimer’s disease, Down syndrome, Central (or Peripheral) Nervous Systems’ disorders or for the enhancement of memory and central nervous system or ...
|
|
WO/2005/007865A1 |
Optically active &agr -methylcysteine derivative is efficiently produced from an inexpensive raw material. An optically active 2-amino-2-methyl-1,3-propanediol derivative monoester is produced by esterifying one of the hydroxyls of 2-ami...
|
|
WO/2005/007810A2 |
The present invention describes a synthetic non-viral vector composition for gene therapy and the use of such compositions for in vitro, ex vivo and/or in vivo transfer of genetic material. The invention proposes a pharmaceutical composi...
|
|
WO/2004/106278A1 |
The invention provides a process for producing N-alkylaminoalkyl (meth)acrylates reduced in the content of low-boiling components, particularly raw material components without troublesome operation and special equipment, that is, a proce...
|
|
WO2004035523B1 |
The invention provides cationic cardiolipin compounds, and methods for synthesizing and using them in liposomal formulation, gene transfection, etc. In particular, the invention provides liposomes comprising cationic cardiolipin analog, ...
|
|
WO/2004/065349A1 |
The invention relates to the compounds of 1-phenyl-2-aminomethyl naphthalene derivatives of the general formula (1), and to methods for their production. 1-Phenyl-2-aminomethyl naphthalenes have antitumoral properties in cell culture mod...
|
|
WO/2004/060854A1 |
The present invention relates to a process for the minimization of volatile organic sulphur byproducts in dimethyl sulfate quaternization of amines made with hypophosphorous acid, which leads to the formation of an odor stable product.
|
|
WO2004039817A9 |
The invention provides new synthetic routes for cardiolipin with different fatty acids and/or alkyl chains with varying chain length and also with or without unsaturation, particularly a short-chain cardiolipin. The methods comprise reac...
|
|
WO/2004/060363A1 |
The present invention relates to a novel method for producing formulations comprising a polynucleotide, block copolymer and cationic surfactant. The formulations produced by the current method are suitable for use in polynucleotide based...
|
|
WO/2004/058682A1 |
Compounds represented by the general formula (I), salts thereof, and hydrates of both: (I) wherein T is a single bond, optionally substituted C1-4 alkylene, or the like; the symbols &dot &dot &dot &dot &dot &dot are each a single bond or...
|
|
WO/2004/058723A1 |
A fungicidally active compound of formula (I): where Het is a substituted 5- or 6-membered heterocyclic ring; R1 is hydrogen, formyl, CO-C1-4 alkyl, COO-C1-4 alkyl, C1-4 alkoxy(C1-4)alkylene, CO-C1-4 alkylenoxy(C1-4)alkyl, propargyl or a...
|
|
WO/2004/045536A2 |
A method for modifying at least one non-ester-containing parent compound, and the compounds produced using such method, which compounds are deployed to temporarily incapacitate at least one subject are disclosed. The modified compounds a...
|
|
WO/2004/045533A2 |
A method and compositions for treating persistent pulmonary hypertension in human newborns that deploys an intravenous infusion of a modified drug formed by adding one or more of a predetermined chemical arrangement to an efficacious par...
|
|
WO/2004/043921A1 |
A novel, improved, and general process for the preparation of 4-aryl-3-hydroxymethyl-1-methylpiperidines is disclosed in the present invention. 4-(4-Fluorophenyl)-3-hydroxymethyl-1-methylpiperidine is a well-known intermediate in making ...
|
|
WO/2004/039763A1 |
The invention features quaternary ammonium compounds of formula I, described herein, and their use in treating asthma, chronic obstructive pulmonary disorder, allergic rhinitis, and infectious rhinitis.
|
|
WO/2004/029004A1 |
The invention relates to the use of an ionic liquid as a matrix liquid for organic synthesis in a homogeneous phase on a soluble medium, said ionic liquid being present in the form of a liquid or solid at room temperature, having formula...
|
|
WO/2004/026817A1 |
An amino alcohol derivative represented by the general formula (1): (1) &lcub e.g., (±)-2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-
methylpentan-1-ol&rcub . It has excellent immunosuppressive activity and is reduced in side ...
|
|
WO/2004/027789A1 |
The use of a composition for polyelectrolytes comprising a quaternary ammonium salt (A) represented by the general formula (1) and an inonic fluid (B) brings about polyelectrolytes which retain excellent characteristics inherent in the i...
|
|
WO/2004/016579A1 |
The invention relates to a method for producing 3-amino-4,4,4-trifluorocrotonic acid esters of formula (I) or their E/Z isomers or tautomeric forms, whereby R1 and R2, independent of one another, represent hydrogen, an optionally substit...
|
|
WO/2004/013086A1 |
Diamine compounds, which in particular are useful as precursors for the production of liquid crystal alignment layers, represented by general formula (I), wherein A1 represents an organic group of 1 to 40 carbon atoms; A2 represents a hy...
|
|
WO/2004/013083A1 |
Nolomirole hydrochloride in a highly purified crystalline polymorphic form I, the process for its preparation and pharmaceutical preparations thereof for the treatment of patients suffering of cardiovascular diseases such as congestive h...
|
|
WO/2004/009034A2 |
The current invention provides novel thiomolybdate derivatives, methods of making novel thiomolybdate derivatives, pharmaceutical compositions of novel thiomolybdate derivatives, methods of using novel thiomolybdate derivatives to treat ...
|
|
WO/2004/004648A2 |
The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound ...
|
